Rohan Nirody

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.

Viking Global /Private Equity/ (Viking Global /Private Equity/) is a private equity subsidiary of Viking Global Investors LP. The firm is headquartered in New York with additional offices in Connecticut, California, London, and Hong Kong.